Bioengineers from Georgia Institute of Technology, Atlanta, Georgia, US have invented a flow-diverter system that offers an effective treatment for aneurysm with active monitoring of intra-aneurysmal haemodynamics.
Three-dimensional (3D) printing shows promise in elucidating answers in the management of complex birth defects, assists in the planning of complex surgical procedures and facilitates stroke rehabilitation, but is beset with various challenges.
Computer and electrical engineers from The State University of New Jersey, US recently designed a cell counting platform that can be integrated with a wristband with readouts linkable to a mobile phone application.
The use of a wearable cardioverter-defibrillator (WCD) may be a suitable alternative for paediatric patients with life-threatening ventricular arrhythmias who are not candidates for implantable cardioverter-defibrillators (ICDs), a recent study showed.
A nasal device that reduces the ability to smell can lead to weight loss and changes in dietary preference for sweet stuff in adults younger than 50 years with obesity, suggesting a novel approach to managing obesity, according to a pilot study presented at the recent European Congress on Obesity (ECO) in Vienna, Austria.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Cardiology - Malaysia digital copy today!
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.